1
|
[Cardiovascular risk factors, haemostasis and antithrombotic treatment in retinal vessel occlusion]. DIE OPHTHALMOLOGIE 2022; 119:1129-1139. [PMID: 36344732 DOI: 10.1007/s00347-022-01751-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 10/13/2022] [Indexed: 11/09/2022]
Abstract
Venous and arterial retinal vascular occlusions are age-related disorders, generally associated with classical cardiovascular risk factors, rather than an isolated ocular disease. As affected patients often also have an increased general risk for other vascular diseases, such as ischemic stroke, an interdisciplinary clarification of cardiovascular risk factors and systemic comorbidities is essential for all patients. Extended hemostaseological investigations may be recommended in those patients who do not match the typical risk profile. Patients at a young age by the time of manifestation, without conventional risk factors as well as patients with an increased risk of developing antiphospholipid syndrome may require a selective clinical investigation including testing for thrombophilic risk factors. Recent studies have clearly demonstrated an association between coagulation and lipid metabolism disorders and the development of both retinal vein and artery occlusions in specific subgroups of patients. Therapeutic approaches to treat retinal vascular occlusions or reduce the long-term risk of recurrences with anticoagulant or antiplatelet drugs have not gained widespread acceptance. However, intravenous thrombolysis may be a valuable treatment option for central retinal artery occlusions within a short time to treatment therapeutic window. For defined disorders of the coagulation system, the administration of antithrombotic drugs to reduce the general vascular risk can be a reasonable approach. This article provides an overview of cardiovascular risk factors, the general vascular risk and the current state of knowledge on ophthalmologically relevant disorders of coagulation and lipid metabolism in patients with venous and arterial retinal vascular occlusions.
Collapse
|
2
|
Sucker C, Dörner T. Aktuelle Aspekte und Strategien zum Einsatz oraler Antikoagulantien
und Plättchenfunktionshemmer in der Praxis. AKTUEL RHEUMATOL 2022. [DOI: 10.1055/a-1857-5295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
ZusammenfassungAufgrund erhöhter venöser und arterieller Risiken und
Begleiterkrankungen bei entzündlich-rheumatischen Erkrankungen sind die
Grundprinzipien der adäquaten medikamentösen Behandlung auch von
Bedeutung in der rheumatologischen Praxis. Bei der oralen Antikoagulation haben
die innovativen Nicht-Vitamin K-abhängigen oralen Antikoagulanzien
(NOAK) die „klassischen“ Antikoagulanzien, die Vitamin
K-Antagonisten (VKA), in vielen Indikationen weitgehend verdrängt;
allerdings finden sich weiterhin Gründe, Patienten anstelle von NOAK mit
VKA zu antikoagulieren. Bei der medikamentösen Hemmung der
Plättchenfunktion werden neben ASS die Thienopyridine Clopidogrel und
Prasugrel sowie Ticagrelor eingesetzt; von besonderer Bedeutung ist eine duale
Plättchenfunktionshemmung (DAPT) mit Kombination verschiedener
Plättchenhemmer. In dieser Übersichtsarbeit wird auf wichtige
Aspekte der oralen Antikoagulation und der oralen
Plättchenfunktionshemmung eingegangen.
Collapse
Affiliation(s)
- Christoph Sucker
- Transfusion Medicine and Hemostasis, COAGUMED Gerinnungszentrum Berlin,
Berlin, Germany
- Internal Medicine and Hemostasis, Medizinische Hochschule Brandenburg,
Brandenburg an der Havel, Germany
| | - Thomas Dörner
- Klinische Hämostaseologie, Med. Klinik mS Rheumatologie und
Klinische Immunologie, Charité Universitätsmedizin Berlin,
Germany
| |
Collapse
|
3
|
Vianna MS, da Silva Praxedes MF, de Araújo VE, Ferreira CB, de Sousa WJFN, Viana CC, Martins MAP. Self-report instruments for assessing adherence to warfarin therapy: a systematic review. Eur J Clin Pharmacol 2021; 77:1765-1781. [PMID: 34292359 DOI: 10.1007/s00228-021-03168-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Accepted: 05/30/2021] [Indexed: 11/25/2022]
Abstract
BACKGROUND The assessment of adherence to warfarin therapy is useful in clinical practice due to its wide variability in dose-response and risks of complications. The aim of this study was to investigate validated instruments used to assess adherence to warfarin therapy. METHODS Information was collected from the MEDLINE (PubMed), LILACS, EMBASE, and Cochrane Library databases. Search strategies were applied for each database, with no time limit or language restriction. Inclusion criteria consisted of study participants of ≥ 18 years of age, from both sexes, on chronic anticoagulation with warfarin for any indication and the use of validated instruments to assess adherence to warfarin therapy. Exclusion criteria consisted of duplicate articles, narrative or systematic reviews, and meta-analyses, as well as case reports/series and experimental studies involving animals. Two independent reviewers performed the following steps: evaluation of titles/abstracts, selection of studies after full reading, data extraction, and evaluation of potential bias. Discrepancies were resolved by a third reviewer. RESULTS Overall, 19 articles were selected for this systematic review, including 17 cross-sectional studies, one cohort study, and one quasi-experimental study, published from 2009 to 2019. The validated instruments identified in this review were Morisky Medication Adherence Scale (MMAS), the eight-item Morisky Medication Adherence Scale (MMAS-8), Measurement of Treatment Adherence (MTA), and Brief Medication Questionnaire (BMQ). Only MMAS-8 was tested for reliability, using the internal consistency assessment, with Cronbach's α range 0.56-0.71. CONCLUSIONS This review highlighted a gap in knowledge regarding the scarcity of validated instruments to assess adherence to warfarin therapy. Limitations were found in instruments that comprised the assessment of the isolated use of medication and the lack of analysis of other relevant therapeutic aspects. Future studies are needed to develop and validate more comprehensive instruments in an attempt to assess adherence to warfarin therapy. PROSPERO Registration number CRD42019128324.
Collapse
Affiliation(s)
- Mayara Sousa Vianna
- Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Pres. Antônio Carlos, 6627, Pampulha, Belo Horizonte, MG, 31270-901, Brazil
| | - Marcus Fernando da Silva Praxedes
- Centro de Ciências da Saúde, Universidade Federal Do Recôncavo da Bahia, Av. do Cajueiro, Cajueiro, Santo Antonio de Jesus, BA, Brazil
| | - Vânia Eloisa de Araújo
- Faculdade de Odontologia, Pontifícia Universidade Católica de Minas Gerais, Av: Dom José Gaspar, 500 Coração Eucarístico, Belo Horizonte, MG, 30535-901, Brazil
| | - Carolina Barbosa Ferreira
- Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Pres. Antônio Carlos, 6627, Pampulha, Belo Horizonte, MG, 31270-901, Brazil
| | - Waleska Jaclyn Freitas Nunes de Sousa
- Faculdade de Medicina da, Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena, 190, Bairro Santa Efigênia, Belo Horizonte, MG, 30130-100, Brazil
| | - Catiane Costa Viana
- Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Pres. Antônio Carlos, 6627, Pampulha, Belo Horizonte, MG, 31270-901, Brazil
| | - Maria Auxiliadora Parreiras Martins
- Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Pres. Antônio Carlos, 6627, Pampulha, Belo Horizonte, MG, 31270-901, Brazil.
- Faculdade de Medicina da, Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena, 190, Bairro Santa Efigênia, Belo Horizonte, MG, 30130-100, Brazil.
| |
Collapse
|